Molecular Devices (MDCC) cut third-quarter guidance, citing softer-than-expected demand from pharmaceutical companies for drug discovery and life sciences products.

The Sunnyvale, Calif., company expects to make 12 to 17 cents a share on revenue of $44 million to $46 million. Analysts were looking for a 29-cent profit on sales of $49 million.